ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions

Journal of Clinical Investigation

Volumn 126, Issue 3, 2016, Pages 892-904

  Olesen, Rikke ^a,b   Swanson, Michael D ^a   Kovarova, Martina ^a   Nochi, Tomonori ^a   Chateau, Morgan ^a   Honeycutt, Jenna B ^a   Long, Julie M ^a   Denton, Paul W ^a   Hudgens, Michael G ^c   Richardson, Amy ^c   Tolstrup, Martin ^b   Østergaard, Lars ^b   Wahl, Angela ^a   Garcia, J Victor ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; TENOFOVIR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; BODILY SECRETIONS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CERVICOVAGINAL SECRETION; COCULTURE; CONTROLLED STUDY; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; TARGET CELL; THYMUS; VIRUS TRANSMISSION; ANIMAL; BLOOD; CELL CULTURE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE; SECRETION (PROCESS); TRANSGENIC MOUSE; TRANSMISSION; UTERINE CERVIX; VAGINA; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CERVIX UTERI; COCULTURE TECHNIQUES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MICROBIAL SENSITIVITY TESTS; RECEPTORS, CCR5; RNA, VIRAL; TENOFOVIR; VAGINA; VIRUS REPLICATION;

EID: 84959909722     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64212     Document Type: Article

References (85)

1. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24(5):621-635.
2. Abdool Karim Q, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.
3. Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
4. Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep. 2012;9(2):160-170.
5. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-F19.
6. Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
7. Van Damme L, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
8. Marrazzo JM, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-518.
9. Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.
10. Baeten JM, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
11. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2011;379(9835):2409-2411.
12. Cohen MS, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
13. Quinn TC, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921-929.
14. Baeten JM, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29.
15. Graham SM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 2007;21(4):501-507.
16. Nagot N, et al. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect. 2008;84(3):167-170.
17. Sheth PM, et al. Persistent HIV RNA shedDing in semen despite effective antiretroviral therapy. AIDS. 2009;23(15):2050-2054.
18. Ronen K, Sharma A, Overbaugh J. HIV transmission biology: translation for HIV prevention. AIDS. 2015;29(17):2219-2227.
19. Melkus MW, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006; 12(11):1316-1322.
20. Sun Z, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med. 2007;204(4):705-714.
21. Denton PW, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16.
22. Denton PW, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One. 2010;5(1):e8829.
23. Denton PW, et al. One percent tenofovir applied topically to humanized BLT mice and used accorDing to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol. 2011;85(15):7582-7593.
24. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005;73(6):1253-1263.
25. Johansson EL, Rudin A, Wassen L, Holmgren J. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 1999;96(2):272-277.
26. Kamat BR, Isaacson PG. The immunocytochemical distribution of leukocytic subpopulations in human endometrium. Am J Pathol. 1987;127(1):66-73.
27. Schulke L, Manconi F, Markham R, Fraser IS. Endometrial dendritic cell populations during the normal menstrual cycle. Hum Reprod. 2008;23(7):1574-1580.
28. Iijima N, Thompson JM, Iwasaki A. Dendritic cells and macrophages in the genitourinary tract. Mucosal Immunol. 2008;1(6):451-459.
29. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464(7286):217-223.
30. Parrish NF, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A. 2013;110(17):6626-6633.
31. Jaspan HB, et al. Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis. 2011;204(10):1550-1556.
32. McKinnon LR, et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol. 2011;187(11):6032-6042.
33. Nkwanyana NN, et al. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology. 2009;128(1 suppl):e746-e757.
34. Saba E, et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 2010;3(3):280-290.
35. Nawaz F, et al. The genotype of early-transmitting HIV gp120s promotes (4)(7)-reactivity, revealing (4)(7)+/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011;7(2):e1001301.
36. Cicala C, et al. The integrin 47 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106(49):20877-20882.
37. Quayle AJ, et al. T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women. J Acquir Immune Defic Syndr. 2007;44(3):292-298.
38. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science. 1987;236(4803):819-822.
39. Morrison CS, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010;24(4):573-582.
40. Iversen AK, et al. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis. 1998;177(5):1214-1220.
41. Cu-Uvin S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14(4):415-421.
42. Hawes SE, Sow PS, Stern JE, Critchlow CW, Gottlieb GS, Kiviat NB. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS. 2008;22(18):2517-2525.
43. Brenchley JM, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749-759.
44. Gumbi PP, et al. CD4 T cell depletion at the cervix during HIV infection is associated with accumulation of terminally differentiated T cells. J Virol. 2011;85(24):13333-13341.
45. Wahl A, et al. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 2012;8(6):e1002732.
46. Wahl A, et al. Breast milk of HIV-positive mothers has potent and species-specific in vivo HIV inhibitory activity. J Virol. 2015;89(21):10868-10878.
47. Chateau M, Swanson MD, Garcia JV. Inefficient vaginal transmission of tenofovir-resistant HIV-1. J Virol. 2013;87(2):1274-1277.
48. Kovarova M, et al. Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog. 2015;11(8):e1005075.
49. Stevceva L, et al. Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251. J Virol. 2002;76(1):9-18.
50. Veazey RS, Marx PA, Lackner AA. Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis. 2003;187(5):769-776.
51. Lennox JL, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796-806.
52. Rockstroh JK, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/ emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807-816.
53. Denton PW, et al. Generation of HIV latency in humanized BLT mice. J Virol. 2012;86(1):630-634.
54. Strategies for Management of Antiretroviral Therapy Study G, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.
55. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001;286(23):2981-2987.
56. Denton PW, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 2014;10(1):e1003872.
57. Mkhize NN, et al. Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy. J Virol. 2010;84(20):10765-10772.
58. Valea D, et al. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology. 2011;8:34.
59. UNAIDS. 2009 AIDS Epidemic Update. Geneva, Switzerland: WHO; 2009.
60. Miller CJ, Alexander NJ, Vogel P, Anderson J, Marx PA. Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J Med Primatol. 1992;21(2-3):64-68.
61. Li Q, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009;458(7241):1034-1038.
62. Howell AL, et al. Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract. J Virol. 1997;71(5):3498-3506.
63. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 1992;257(5068):383-387.
64. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol. 2006;6(11):859-868.
65. Arrighi JF, et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med. 2004;200(10):1279-1288.
66. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science. 2003;300(5623):1295-1297.
67. Geijtenbeek TB, et al. DC-SIGN, a dendritic cell-specific HIV-1-binDing protein that enhances trans-infection of T cells. Cell. 2000;100(5):587-597.
68. Hladik F, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26(2):257-270.
69. Miller CJ, Hu J. T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. J Infect Dis. 1999;179(suppl 3):S413-S417.
70. Gupta P, et al. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol. 2002;76(19):9868-9876.
71. Zhang Z, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286(5443):1353-1357.
72. Miller CJ, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005;79(14):9217-9227.
73. Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A. 2005;102(32):11504-11509.
74. Wheeler LA, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest. 2011;121(6):2401-2412.
75. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol. 2005;79(19):12164-12172.
76. Reynolds MR, et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol. 2005;79(14):9228-9235.
77. Ferenbach D, Hughes J. Macrophages and dendritic cells: what is the difference? Kidney Int. 2008;74(1):5-7.
78. Strobl H, et al. Identification of CD68+linperipheral blood cells with dendritic precursor characteristics. J Immunol. 1998;161(2):740-748.
79. Segerer S, et al. Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int. 2008;74(1):37-46.
80. de Saint-Vis B, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998;160(4):1666-1676.
81. Woltman AM, et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int. 2007;71(10):1001-1008.
82. Lazarovits AI, et al. Lymphocyte activation antigens. J Immunol. 1984;133(4):1857-1862.
83. Palmer S, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41(10):4531-4536.
84. Rubenstein LM, Davis CS. Estimation of the average correlation coefficient for stratified bivariate data. Stat Med. 1999;18(5):567-580.
85. Efron B, Tibshirani R. An Introduction To The Bootstrap. 1st ed. London, United Kingdom: Chapman and Hall/CRC; 1993.